Japan
· Delayed Price · Currency is JPY Stella Pharma Statistics
Total Valuation
Stella Pharma has a market cap or net worth of JPY 13.51 billion. The enterprise value is 10.87 billion.
| Market Cap | 13.51B |
| Enterprise Value | 10.87B |
Important Dates
The next estimated earnings date is Friday, May 9, 2025.
| Earnings Date | May 9, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Stella Pharma has 34.03 million shares outstanding. The number of shares has increased by 7.01% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 34.03M |
| Shares Change (YoY) | +7.01% |
| Shares Change (QoQ) | +0.55% |
| Owned by Insiders (%) | 4.28% |
| Owned by Institutions (%) | 13.17% |
| Float | 20.63M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 40.17 |
| PB Ratio | 4.54 |
| P/TBV Ratio | 4.62 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -16.30 |
| EV / Sales | 33.66 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 20.67, with a Debt / Equity ratio of 0.27.
| Current Ratio | 20.67 |
| Quick Ratio | 14.96 |
| Debt / Equity | 0.27 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -222.67 |
Financial Efficiency
Return on equity (ROE) is -23.64% and return on invested capital (ROIC) is -11.24%.
| Return on Equity (ROE) | -23.64% |
| Return on Assets (ROA) | -9.27% |
| Return on Invested Capital (ROIC) | -11.24% |
| Return on Capital Employed (ROCE) | -13.80% |
| Revenue Per Employee | 7.34M |
| Profits Per Employee | -15.16M |
| Employee Count | 44 |
| Asset Turnover | 0.07 |
| Inventory Turnover | 0.04 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +32.78% in the last 52 weeks. The beta is 0.98, so Stella Pharma's price volatility has been similar to the market average.
| Beta (5Y) | 0.98 |
| 52-Week Price Change | +32.78% |
| 50-Day Moving Average | 464.14 |
| 200-Day Moving Average | 468.07 |
| Relative Strength Index (RSI) | 39.19 |
| Average Volume (20 Days) | 251,535 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Stella Pharma had revenue of JPY 323.00 million and -667.00 million in losses. Loss per share was -20.41.
| Revenue | 323.00M |
| Gross Profit | 275.00M |
| Operating Income | -668.00M |
| Pretax Income | -665.00M |
| Net Income | -667.00M |
| EBITDA | -633.00M |
| EBIT | -668.00M |
| Loss Per Share | -20.41 |
Balance Sheet
The company has 3.45 billion in cash and 813.00 million in debt, giving a net cash position of 2.64 billion or 77.54 per share.
| Cash & Cash Equivalents | 3.45B |
| Total Debt | 813.00M |
| Net Cash | 2.64B |
| Net Cash Per Share | 77.54 |
| Equity (Book Value) | 2.97B |
| Book Value Per Share | 87.38 |
| Working Capital | 4.66B |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 85.14%, with operating and profit margins of -206.81% and -206.50%.
| Gross Margin | 85.14% |
| Operating Margin | -206.81% |
| Pretax Margin | -205.88% |
| Profit Margin | -206.50% |
| EBITDA Margin | -195.98% |
| EBIT Margin | -206.81% |
| FCF Margin | n/a |
Dividends & Yields
Stella Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.01% |
| Shareholder Yield | -7.01% |
| Earnings Yield | -4.94% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Stella Pharma has an Altman Z-Score of 4.37.
| Altman Z-Score | 4.37 |
| Piotroski F-Score | n/a |